J Gerardo Garcia-Lerma

Summary

Affiliation: Centers for Disease Control and Prevention
Country: USA

Publications

  1. doi request reprint Animal models of antiretroviral prophylaxis for HIV prevention
    J Gerardo Garcia-Lerma
    Laboratory Branch, Division of HIV AIDS Prevention, National Center for HIV, Hepatitis, STD, and Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Curr Opin HIV AIDS 7:505-13. 2012
  2. pmc Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons
    J G Garcia-Lerma
    HIV and Retrovirology Branch, Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Proc Natl Acad Sci U S A 98:13907-12. 2001
  3. doi request reprint Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection
    J Gerardo Garcia-Lerma
    Division of HIV AIDS Prevention, National Center for HIV, Hepatitis, STD, and Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329, USA
    Sci Transl Med 2:14ra4. 2010
  4. pmc Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors
    J Gerardo Garcia-Lerma
    Division of HIV AIDS Prevention, National Center for HIV, Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329, USA
    J Virol 85:6610-7. 2011
  5. pmc Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir
    J Gerardo Garcia-Lerma
    Division of HIV AIDS Prevention, National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    PLoS Med 5:e28. 2008
  6. doi request reprint Oral pre-exposure prophylaxis for HIV prevention
    J Gerardo Garcia-Lerma
    Division of HIV AIDS Prevention, National Center for HIV, Hepatitis, STD, and Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329, USA
    Trends Pharmacol Sci 31:74-81. 2010
  7. ncbi request reprint Diversity of thymidine analogue resistance genotypes among newly diagnosed HIV-1-infected persons
    J Gerardo Garcia-Lerma
    Laboratory Branch, Division of HIV AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS G 19, Atlanta, GA 30333, USA
    J Antimicrob Chemother 56:265-9. 2005
  8. pmc Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine
    J Gerardo Garcia-Lerma
    HIV and Retrovirology Branch, Division of AIDS, STD, and TB Laboratory Research, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Virol 78:7545-52. 2004
  9. ncbi request reprint Rapid biochemical assays for phenotypic drug resistance testing of HIV-1
    J Gerardo Garcia-Lerma
    HIV and Retrovirology Branch, Division of AIDS, STD, and TB Laboratory Research, MS G 19, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA
    J Antimicrob Chemother 50:771-4. 2002
  10. pmc A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation
    J Gerardo Garcia-Lerma
    HIV and Retrovirology Branch, Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Virol 77:5685-93. 2003

Collaborators

Detail Information

Publications36

  1. doi request reprint Animal models of antiretroviral prophylaxis for HIV prevention
    J Gerardo Garcia-Lerma
    Laboratory Branch, Division of HIV AIDS Prevention, National Center for HIV, Hepatitis, STD, and Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Curr Opin HIV AIDS 7:505-13. 2012
    ....
  2. pmc Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons
    J G Garcia-Lerma
    HIV and Retrovirology Branch, Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Proc Natl Acad Sci U S A 98:13907-12. 2001
    ..The increased ability for selecting resistance mutations defines this class of WT HIV-1 and highlights the higher potential of these viruses to compromise the efficacy of antiretroviral therapy...
  3. doi request reprint Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection
    J Gerardo Garcia-Lerma
    Division of HIV AIDS Prevention, National Center for HIV, Hepatitis, STD, and Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329, USA
    Sci Transl Med 2:14ra4. 2010
    ..They strengthen the possibility of developing feasible, cost-effective strategies to prevent HIV transmission in humans...
  4. pmc Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors
    J Gerardo Garcia-Lerma
    Division of HIV AIDS Prevention, National Center for HIV, Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329, USA
    J Virol 85:6610-7. 2011
    ....
  5. pmc Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir
    J Gerardo Garcia-Lerma
    Division of HIV AIDS Prevention, National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    PLoS Med 5:e28. 2008
    ..We evaluated daily and intermittent PrEP regimens of increasing antiviral activity in a macaque model that closely resembles human transmission...
  6. doi request reprint Oral pre-exposure prophylaxis for HIV prevention
    J Gerardo Garcia-Lerma
    Division of HIV AIDS Prevention, National Center for HIV, Hepatitis, STD, and Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329, USA
    Trends Pharmacol Sci 31:74-81. 2010
    ....
  7. ncbi request reprint Diversity of thymidine analogue resistance genotypes among newly diagnosed HIV-1-infected persons
    J Gerardo Garcia-Lerma
    Laboratory Branch, Division of HIV AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS G 19, Atlanta, GA 30333, USA
    J Antimicrob Chemother 56:265-9. 2005
    ..In this leading article, I discuss these findings and the potential impact of these unique reverse transcriptase (RT) genotypes on evolution of resistance and treatment responses...
  8. pmc Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine
    J Gerardo Garcia-Lerma
    HIV and Retrovirology Branch, Division of AIDS, STD, and TB Laboratory Research, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Virol 78:7545-52. 2004
    ..Our study emphasizes the need for clinical studies to better define the impact of these mutants on treatment responses and evolution of resistance...
  9. ncbi request reprint Rapid biochemical assays for phenotypic drug resistance testing of HIV-1
    J Gerardo Garcia-Lerma
    HIV and Retrovirology Branch, Division of AIDS, STD, and TB Laboratory Research, MS G 19, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA
    J Antimicrob Chemother 50:771-4. 2002
  10. pmc A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation
    J Gerardo Garcia-Lerma
    HIV and Retrovirology Branch, Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Virol 77:5685-93. 2003
    ..These findings highlight the complexity of the genetic pathways of d4T resistance and its phenotypic expression...
  11. pmc Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxis
    Ellen N Kersh
    Division of HIV AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    J Infect Dis 206:770-9. 2012
    ..We addressed the hypothesis that SHIV(SF162P3) infection despite active PrEP results in altered early immune parameters, compared with untreated infection...
  12. doi request reprint Short communication: no evidence of occult SHIV infection as demonstrated by CD8+ cell depletion after chemoprophylaxis-induced protection from mucosal infection in rhesus macaques
    Ellen N Kersh
    Division of HIV AIDS Prevention, NCHHSTP, CCID, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    AIDS Res Hum Retroviruses 24:543-6. 2008
    ..These data provide important information for PrEP usage to prevent HIV transmission, and fully support the continued pursuit of PrEP prevention measures in humans...
  13. ncbi request reprint High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients
    Silvina Masciotra
    Laboratory Branch, Division of HIV AIDS Prevention, National Center for HIV AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    AIDS 21:2503-11. 2007
    ..Dried blood spots (DBS) are a convenient alternative to plasma for drug resistance testing in resource-limited settings. We investigated the correlation between resistance genotypes generated from DBS and plasma...
  14. pmc Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada
    Mian er Cong
    Laboratory Branch, CDC, Division of HIV AIDS Prevention, MS G45, 1600 Clifton Road, Atlanta, GA 30329, USA
    J Virol 85:7933-6. 2011
    ..Increased susceptibility to tenofovir due to M184V and other factors, including residual antiviral activity by FTC and/or reduced virus fitness due to M184V, may all have contributed to the observed protection...
  15. pmc Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing
    Amanda McNulty
    Division of HIV AIDS Prevention, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, USA
    J Clin Microbiol 45:517-21. 2007
    ..The amplification of proviral DNA from DBS highlights the need for a wider evaluation of the concordance of resistance genotypes between plasma and DBS...
  16. pmc T cell chemo-vaccination effects after repeated mucosal SHIV exposures and oral pre-exposure prophylaxis
    Ellen N Kersh
    Division of HIV AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
    PLoS ONE 6:e19295. 2011
    ..Our findings highlight the importance of monitoring these responses in clinical PrEP trials and suggest that a combination of vaccines and PrEP potentially might enhance efficacy...
  17. doi request reprint Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques
    Mian er Cong
    Division of HIV AIDS Prevention, National Center for HIV, Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, USA
    Virology 412:435-40. 2011
    ..Our results in limited number of macaques suggest that the reduction in fitness due to M184V and K65R decreases virus transmissibility, and identify in vitro infectivity parameters that associate with mucosal transmissibility...
  18. pmc Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen
    Jessica Radzio
    Laboratory Branch, Division of HIV AIDS Prevention, National Center for HIV, Hepatitis, STD, and Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
    PLoS ONE 7:e50632. 2012
    ..Here we examined FTC and tenofovir TFV exposure in vaginal tissues after oral dosing and assessed if peri-coital Truvada also protects macaques against vaginal SHIV infection...
  19. pmc Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue
    Charles Dobard
    Laboratory Branch and Quantitative Sciences and Data Management Branch, Division of HIV AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    J Virol 86:718-25. 2012
    ..The identification of protective TFV-DP concentrations in vaginal lymphocytes may facilitate the evaluation of improved delivery methods of topical TFV and inform clinical studies...
  20. doi request reprint On-line coupling of anion exchange and ion-pair chromatography for measurement of intracellular triphosphate metabolites of reverse transcriptase inhibitors
    Zsuzsanna Kuklenyik
    Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, United States
    J Chromatogr B Analyt Technol Biomed Life Sci 877:3659-66. 2009
    ..Limits of detection were 9, 200 and 75 pg per sample for TFV-DP (448/176 m/z), FTC-TP (488/130 m/z) and 3TC-TP (468/119 m/z), respectively...
  21. pmc Susceptibility to repeated, low-dose, rectal SHIVSF162P3 challenge is independent of TRIM5 genotype in rhesus macaques
    Katherine Butler
    Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    AIDS Res Hum Retroviruses 29:1091-4. 2013
    ..The finding that TRIM5 alleles do not restrict mucosal infection or ensuing replication rates suggests that SHIVSF162P3 is indeed suitable for RLD experimentation...
  22. doi request reprint Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis
    Kelly A Curtis
    Laboratory Branch, Division of HIV AIDS Prevention, National Center for HIV AIDS, Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Acquir Immune Defic Syndr 57:355-62. 2011
    ....
  23. pmc Prophylactic efficacy of oral emtricitabine and tenofovir disoproxil fumarate combination therapy against a tenofovir-resistant simian/human immunodeficiency virus containing the K65R mutation in macaques
    Mian er Cong
    Division of HIV AIDS Prevention, National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
    J Infect Dis 208:463-7. 2013
    ..028), although 4 of 6 FTC/TDF-treated macaques were infected at the end of the challenges. These findings highlight the need to closely monitor PrEP efficacy in areas with prevalent K65R. ..
  24. doi request reprint Minority HIV mutation detection in dried blood spots indicates high specimen integrity and reveals hidden archived drug resistance
    Xierong Wei
    Laboratory Branch, Division of HIV AIDS Prevention, National Centers for HIV AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Rd, NE, MS G45 Atlanta, GA 30333, USA
    J Clin Virol 50:148-52. 2011
    ..Dried blood spots (DBS) could serve as an attractive, cost-effective alternative to plasma for HIV drug resistance testing...
  25. pmc The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions
    Mian er Cong
    Division of HIV AIDS Prevention, National Center for HIV, Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333, USA
    J Virol 81:3037-41. 2007
    ..We conclude that the persistence of transmitted RT mutants might range widely on the basis of fitness and that the modulation of fitness cost by mutational interactions will be a critical determinant of persistence...
  26. pmc Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis
    Qi Zheng
    National Center for HIV, Hepatitis, STD, and Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Retrovirology 9:40. 2012
    ..We investigated viral evolution dynamics in a macaque model of PrEP consisting of repeated rectal exposures to SHIV162P3 in the presence of PrEP...
  27. pmc HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 degrees C
    Ae S Youngpairoj
    Laboratory Branch, Division of HIV AIDS Prevention, National Center for HIV AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
    J Antimicrob Chemother 61:1217-20. 2008
    ..We recently showed that HIV-1 can be efficiently genotyped from DBSs stored at -20 degrees C for prolonged periods (0.5-4 years). Here, we evaluated the efficiency of genotyping from DBSs stored at 4 degrees C for 1 year...
  28. ncbi request reprint The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities
    Hillard S Weinstock
    Division of HIV AIDS Prevention, Surveillance and Epidemiology, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Infect Dis 189:2174-80. 2004
    ..The prevalence and characteristics of persons with newly diagnosed human immunodeficiency virus (HIV) infections with or without evidence of mutations associated with drug resistance have not been well described...
  29. doi request reprint Evaluation of the lymphocyte trafficking drug FTY720 in SHIVSF162P3-infected rhesus macaques
    Ellen N Kersh
    Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Antimicrob Chemother 63:758-62. 2009
    ..We address here whether therapeutic use of FTY720 in simian human immunodeficiency virus (SHIV)-infected rhesus macaques could also decrease viraemia...
  30. doi request reprint Repeated rectal SHIVSF162P3 exposures do not consistently induce sustained T cell responses prior to systemic infection in the repeat-low dose preclinical macaque model
    Ellen N Kersh
    Division of HIV AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    AIDS Res Hum Retroviruses 25:905-17. 2009
    ..Our results provide further insights into the repeat exposure macaque model. We find that this model can be used for testing biomedical prevention strategies without concern of eliciting a systemic vaccination effect...
  31. pmc Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine
    Urvi M Parikh
    Laboratory Branch, Division of HIV AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
    J Virol 83:10358-65. 2009
    ..Thus, single drugs with durable antiviral activity can provide highly effective topical prophylaxis and overcome the need for noncoital use or for drug combinations which are more complex and costly to formulate and approve...
  32. ncbi request reprint Natural resistance of human immunodeficiency virus type 2 to zidovudine
    Patrick Reid
    Laboratory Branch, Division of HIV AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
    Virology 336:251-64. 2005
    ..Our results demonstrate that the activity of AZT on HIV-2 is lower than previously thought, and emphasize the need for novel antiretroviral drugs specific for HIV-2...
  33. pmc Lack of Prophylactic Efficacy of Oral Maraviroc in Macaques despite High Drug Concentrations in Rectal Tissues
    Ivana Massud
    Laboratory Branch, Division of HIV AIDS Prevention, National Center for HIV, Hepatitis, STD, and Tuberculosis Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    J Virol 87:8952-61. 2013
    ..The increases in CD3(+)/CCR5(+) cells seen during MVC treatment point to unique immunological effects of CCR5 inhibition by MVC. The implications of these immunological effects on PrEP with MVC require further evaluation. ..
  34. ncbi request reprint Effect of mobile phase pH and organic content on LC-MS analysis of nucleoside and nucleotide HIV reverse transcriptase inhibitors
    Zsuzsanna Kuklenyik
    Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, USA
    J Chromatogr Sci 47:365-72. 2009
    ..1 mL plasma (10 pg on column) and coefficients of variation from 5% to 15% in the high ng/mL concentration range and from 16% to 20% in the low ng/mL concentration range...
  35. pmc Measuring enzymatic HIV-1 susceptibility to two reverse transcriptase inhibitors as a rapid and simple approach to HIV-1 drug-resistance testing
    Dieter Hoffmann
    Laboratory Branch, Division of HIV AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
    PLoS ONE 6:e22019. 2011
    ..This enzymatic testing is subtype-independent and can assist in the clinical management of diverse populations particularly in resource-limited settings...
  36. pmc Rapid decline in the efficiency of HIV drug resistance genotyping from dried blood spots (DBS) and dried plasma spots (DPS) stored at 37 degrees C and high humidity
    J Gerardo Garcia-Lerma
    Laboratory Branch, Division of HIV AIDS Prevention, National Center for HIV AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Antimicrob Chemother 64:33-6. 2009
    ..We sought to investigate how extreme conditions could affect the short-term ability to amplify and genotype HIV from DBS...